Compare BCBP & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | CNTB |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 157.1M |
| IPO Year | N/A | 2021 |
| Metric | BCBP | CNTB |
|---|---|---|
| Price | $8.17 | $2.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $9.25 | $8.50 |
| AVG Volume (30 Days) | 79.7K | ★ 653.9K |
| Earning Date | 10-27-2025 | 11-13-2025 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $64,592,000.00 | $762,000.00 |
| Revenue This Year | $23.06 | N/A |
| Revenue Next Year | $3.55 | $38,289.22 |
| P/E Ratio | $164.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.41 | $0.51 |
| 52 Week High | $13.37 | $3.28 |
| Indicator | BCBP | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 56.93 |
| Support Level | $7.85 | $2.52 |
| Resistance Level | $8.12 | $2.87 |
| Average True Range (ATR) | 0.19 | 0.36 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 85.71 | 56.21 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.